






















| Therapy | Target/Modality | Indications | Preclinical | Phase 1 | Phase 2 | Phase 2 Reg / Phase 3 |
|---------------------------|--------------------------------|-------------------------------|---|--|---|--|
| Magrolimab + Azacitidine | CD47 antibody | MDS | | | |  FortySeven ¹ |
| AFM13 | CD30/CD16A bispecific engager | PTCL | | | |  affimed |
| CPI-0610 +/- Ruxolitinib | BET small molecule | MPN | | | |  Constellation PHARMACEUTICALS |
| Duvelisib + Romidepsin | PI3Kδ/γ small molecule | PTCL | | | |  Verastem ² Oncology |
| Magrolimab + Rituximab | CD47 antibody | DLBCL | | |  FortySeven ¹ | |
| Cobomarsen | miR-155 small molecule | CTCL | | |  miRagen ³ | |
| K-NK002 | NK Cell Therapy | AML/MDS | | |  Kiadis ⁴ | |
| Cusatuzumab + Azacitidine | CD70 antibody | MDS | | |  argenx ⁵ | |
| Cusatuzumab + Ven + Aza | CD70 antibody | AML | |  argenx ⁵ | | |
| STRO-001 | CD74 antibody drug conjugate | MM/DLBCL/ MCL/FL | |  SUTRO [®] BIOPHARMA | | |
| Mavorixafor + Ibrutinib | CXCR4 small molecule | Waldenström macroglobulinemia | |  X4 PHARMACEUTICALS | | |
| SEL120 | CDK8/19 small molecule | AML/MDS | |  RYVU THERAPEUTICS | | |
| PVX-410 + ACY-241 +/- Len | XBP1/CD138/CS1 vaccine | Smoldering myeloma | |  OncoPep | | |
| KO-539 | Menin small molecule | MLL leukemia | |  KURA ⁶ ONCOLOGY | | |
| NEXI-001 | T Cell Therapy | AML | |  NexImmune | | |
| NEXI-002 | T Cell Therapy | Multiple myeloma | |  NexImmune | | |
| BTX-A51 | CK1-α/CDK7/CDK9 small molecule | AML/MDS | |  BioTheryX | | |
| PROTACs | IRAK4 & STAT3 small molecules | Lymphoma |  KYMERA | | | |
| <i>in vivo</i> CAR | T Cell Therapy | Lymphoma |  ABINTUS | | | |

1: Acquired by Gilead ♦ 2: Licensed to Secura Bio ♦ 3: Deprioritized ♦ 4: Acquisition by Sanofi announced ♦ 5: Collaboration with Janssen ♦ 6: Licensed from University of Michigan